Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research.
For the 65 million people worldwide with epilepsy, progress is unacceptably slow. Children with uncontrollable seizures frequently face a lifetime of challenges including misunderstandings about epilepsy, discrimination, and other epilepsy-related problems. Mortality rates among people with epilepsy are three times the rate of the general population, and sudden death rates are more than twenty times higher.
THE NEED FOR MORE RESEARCH IS CLEAR:
After nearly 20 years of no new FDA-approved anti-epileptic drugs, Vigabatrin is introduced, marking the second generation of AEDs.
FDA and Burroughs Welcome Committee define “Sudden Unexpected Death in Epilepsy, or “SUDEP.”
Vagus Nerve Stimulator is approved as a non-pharmaceutical treatment option, the first following ketogenic diet and brain surgery.
CURE is founded by Susan Axelrod to advance the field of epilepsy research in honor of her daughter Lauren.
108th U.S. Congress passes a resolution recognizing November as National Epilepsy Awareness Month.
CURE launches SUDEP Signature Research Program. CURE funds first SUDEP research grant to Carl L. Faingold, PhD.
Purple Day® is celebrated worldwide in support of people with epilepsy for the first time.
NINDS and CURE develop CWOW concept to advance epilepsy research. Eslicarbazepine is introduced as the first of a new wave of 3rd generation anti-epileptic drugs.
FDA approves the use of the Responsive Neuropace Stimulator as a non-pharmaceutical treatment option for people with intractable epilepsy.